Quanterix to Present at the Canaccord Genuity 38th Annual Growth Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Jul 30, 2018--Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will present at the Canaccord Genuity 38th Annual Growth Conference, on Thursday, Aug. 9, 2018 at 10 a.m., EDT at the InterContinental Boston. Hrusovsky will also be available for one-on-one meetings at the conference.
To access the live webcast of Quanterix’ presentation, please visit the News & Events page within the Investors section of the Quanterix website at www.quanterix.com. Replays of the webcast will be available for 90 days following each conference.
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease through ultrasensitive detection of biomarkers and to accelerate drug development and approval. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, immunology and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts. For additional information, please visit https://www.quanterix.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release include, but are not limited to Simoa’s potential ability to change the way in which healthcare is provided today, and are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180730005093/en/
CONTACT: Quanterix Corporation
Lindsay Poole, 617-502-4300
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: TECHNOLOGY OTHER TECHNOLOGY HEALTH BIOTECHNOLOGY GENERAL HEALTH
SOURCE: Quanterix Corporation
Copyright Business Wire 2018.
PUB: 07/30/2018 09:00 AM/DISC: 07/30/2018 09:00 AM